Reimbursement & Policy
The Reimbursement & Policy working group (RWG) was formed among a diverse group of market access, health economics and regulatory staff. In order to improve patient outcomes, the RWG has mobilized resources to support the growth of ctDNA testing in a public and immediate manner through positive changes to payer coverage policies. We are working collectively, above brand, to demonstrate the value of liquid biopsy-based applications.
THE RWG’S INITIATIVES FOCUS ON:
ADVOCACY
ECONOMIC VALUE
EDUCATION
Focus Groups
MEMBER EDUCATION
Maude Champagne, Illumina
There is significant diversity in the work being done by BLOODPAC members. This subgroup ensures that coverage and policy changes are shared with the broader reimbursement and policy team. It creates a space for sharing best practices and mobilizing across industries to increase liquid biopsy access.
RISK HOLDER ENGAGEMENT
Suzanne Belinson, Tempus
This subgroup aims to educate payers, laboratory benefit managers and other risk holders on the evidence-based clinical utility, economic value and patient benefit of liquid biopsy. Working collaboratively with risk holders to align incentives and develop evidence frameworks is also primary to the mission of this group.
ADVOCACY
Robert Dumanois, Thermo Fisher Scientific
The focus of the subgroup is to generate comment letters on topics related to the use of liquid biopsy in the clinical setting. This includes public comments on CMS topics, including NCDs and LCDs, commercial payer medical policy issues, professional guidelines, and other ad hoc topics identified by the reimbursement working group. Examples of recent correspondence may be seen here.